INTRATUMORAL ADAPTIVE IMMUNOSUPPRESSION AND TYPE 17 IMMUNITY IN MISMATCH REPAIR PROFICIENT COLORECTAL TUMORS

PURPOSE: Approximately 10% of mismatch repair proficient (MMRp) colorectal cancer (CRC) patients showed clinical benefit to anti-PD-1 monotherapy (). We sought to identify biomarkers that delineate patients with immunoreactive CRC and to explore new combinatorial immunotherapy strategies that can im...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Llosa, Nicolas J., Luber, Brandon, Tam, Ada J., Smith, Kellie N., Siegel, Nicholas, Awan, Anas H., Fan, Hongni, Oke, Teniola, Zhang, JiaJia, Domingue, Jada, Engle, Elizabeth L., Roberts, Charles A., Bartlett, Bjarne R., Aulakh, Laveet K., Thompson, Elizabeth D., Taube, Janis M., Durham, Jennifer N., Sears, Cynthia L, Le, Dung T, Diaz, Luis A., Pardoll, Drew M., Wang, Hao, Anders, Robert A., Housseau, Franck
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726531/
https://ncbi.nlm.nih.gov/pubmed/31061070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0114
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados